Formatech, Inc Receives Warning Letter at Facility Manufacturing Clinical Trial Materials Comment: Clinical Supply Manufacturing (CMO) facilities are not customarily audited when they produce Phase 1, Phase 2 or Phase 3 Clinical Trial materials.  A CMO would not typically receive its initial FDA audit until it requests its Pre-Approval Inspection (PAI) for a new drug.  … [Read more...]